Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even Conference call to be held today, March 9, ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in ...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer ...

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

FARE's indicator report tracks the growing public health challenge of food allergy in the United States—a top-tier public ...

Thirteen members of Vashon High School’s Outdoor Adventure Club earned their Wilderness First Aid certificates through the Bellingham-based organization Backcountry Medical Guides.

Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi will manufacture the finished doses for hospitals and clinics across the country. The partnership reinforces the ...

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and ...

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...